Quantum BioPharma Ltd. (NASDAQ: QNTM) is advancing its lead compound Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis after the U.S. Food and Drug Administration cleared its Investigational New Drug application. The clearance marks a critical regulatory milestone for a therapy that takes a different approach to treating MS, focusing on repairing myelin rather than broadly suppressing the immune system.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). The enzyme PAD2 is believed to play a key role in demyelination, the process by which the protective myelin sheath around nerve fibers is degraded. By targeting PAD2 directly, Lucid-MS is designed to prevent and reverse myelin degradation, potentially altering the course of MS. This mechanism contrasts with most existing MS therapies, which primarily modulate or suppress immune activity to reduce relapses but do not directly promote myelin repair.
The FDA's acceptance of the IND application allows Quantum BioPharma to proceed with clinical testing in humans. A phase 2 trial will evaluate whether Lucid-MS can safely and effectively impact disease progression in MS patients. If successful, the drug could offer a new treatment option for a condition where significant unmet need remains, particularly for patients with progressive forms of MS who respond poorly to current immunomodulatory therapies.
Quantum BioPharma is also collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a method to visualize and measure demyelination in the brain. The ability to directly image myelin damage could enhance the evaluation of therapies like Lucid-MS by providing objective biomarkers of treatment response. Such imaging tools may also accelerate clinical trial timelines and improve patient selection.
The company is developing Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc. In addition to its MS program, Quantum BioPharma has spun out an over-the-counter product called UNBUZZD to Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% in perpetuity. Quantum also retains full rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The broader biopharmaceutical industry continues to see advancements in areas of high unmet need. For example, Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. These developments underscore the importance of continued innovation across therapeutic areas.
For Quantum BioPharma, the FDA clearance represents a significant step forward. It positions the company to test a potentially disease-modifying therapy in MS, a chronic and often debilitating neurological condition. If Lucid-MS succeeds in clinical trials, it could become a first-in-class treatment that addresses the underlying pathology of demyelination, offering hope to patients who currently have limited options for halting or reversing disability. The phase 2 trial will be closely watched by investors and the medical community as it could validate a novel approach to MS treatment.
To view the full press release, visit https://ibn.fm/lCey9. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
